TP Therapeutics pipeline includes potent inhibitors targeting established oncogene drivers, and the acquired resistance (including secondary resistant mutations, bypass mechanisms, and epithelial–mesenchymal transition) that develop from today’s current available therapies.  Our team is also working on newly identified novel disease-driven targets, and targets regulating the tumor microenvironment and tumor immunity.

 

 

Our leading project TPX-0005 (ropotrectinib) is now in clinical development (TRIDENT-1, NCT03093116).  More information about TRIDENT-1 is available at ClinicalTrials.gov.  Here is the official title for this clinical trial:  

A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)

 

Here is our first presentation of the interim data from its ongoing Phase 1/2 open-label, dose-escalation trial of TPX-0005, a potent and selective investigational inhibitor for ALK, ROS1, and TRK family at Annual American Society of Clinical Oncology (ASCO) Meeting, June 1-5, 2018, Chicago, Illinois.

A phase 1 study of the next-generation ALK/ROS1/TRK inhibitor Ropotrectinib (TPX-0005) in patients with advanced ALK/ROS1/NTRK+ cancers (TRIDENT-1)

 

Here are three TPX-0005 (ropotrectinib) posters on NTRK, ROS1, and ALK presented at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications, October 26-30, 2017, Philadelphia, Pennsylvania

  1. TPX-0005, a highly potent TRK inhibitor, effectively overcomes clinical-resistance TRK mutations including solvent front mutants TRKA G595R, TRKB G639R, and TRKC G623R
  2. TPX-0005, a supreme ROS1 inhibitor, overcomes crizotinib-resistant ROS1 mutations including solvent front mutation G2032R and gatekeeper mutation L2026M
  3. TPX-0005, a polypharmacology inhibitor, overcomes ALK treatment resistances from acquired mutations, bypass signaling and EMT

 

Here is a recent poster on TPX-0005 (ropotrectinib) at The IASLC 18th World Conference on Lung Cancer (WCLC), October 15-18, 2017, Yokohama, Japan.

  1. TPX-0005 with an EGFR tyrosine kinase inhibitor (TKI) overcomes innate resistance in EGFR mutant NSCLC

 

Here are two AACR abstracts on TPX-0005 (ropotrectinib):

  1. Ending the endless acquired tyrosine kinase resistance mutations — Design of TPX-0005, a multi-target ALK/ROS1/TRK inhibitor with broad spectrum activity against wild-type and mutants including ALK G1202R, ROS1 G2032R and TRKA G595R
  2. The novel, rationally-designed, ALK/SRC inhibitor TPX-0005 overcomes multiple acquired resistance mechanisms to current ALK inhibitors

For more detailed information, please contact us at info@tptherapeutics.com.